Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rash

BACKGROUND: Lenalidomide is approved for treating transfusion-dependent anemia due to lower-risk del(5q) myelodysplastic syndromes (MDS). In clinical trials, rash was common, although severe rash was infrequent. To examine rash in patients with MDS treated with lenalidomide in the real world, the Ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Weiss, Lilia, Gary, Dianna, Swern, Arlene S, Freeman, John, Sugrue, Mary M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567225/
https://www.ncbi.nlm.nih.gov/pubmed/26379438
http://dx.doi.org/10.2147/TCRM.S86449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567225/
https://www.ncbi.nlm.nih.gov/pubmed/26379438
http://dx.doi.org/10.2147/TCRM.S86449

Ejemplares similares